Core Viewpoint - Changfeng Pharmaceutical (02652.HK) made its debut on the Hong Kong Stock Exchange on October 8, 2023, with a significant opening increase of 218.64% [1] Group 1: Stock Performance - The opening price was set at HKD 47 per share, with the stock price peaking at over 220% during trading [1] - As of the latest update, the stock has slightly retraced to HKD 41.6 per share, reflecting a still substantial increase of 182% [1] Group 2: Company Focus - Changfeng Pharmaceutical specializes in the research, development, production, and commercialization of inhalation technology and inhalation drugs [1] - The company targets the treatment of respiratory diseases and has developed a diverse product portfolio that addresses a wide range of patients, medical specialties, and treatment areas [1]

Market Overview - The Hong Kong stock market opened slightly lower, with the Hang Seng Index down by 0.21% and the Hang Seng Tech Index down by 0.11%. Both indices continued to decline, with the Hang Seng Index down by 1.5% and the Hang Seng Tech Index down by nearly 2% at the time of reporting [1] - Gold stocks showed strong performance, with notable increases: Tongguan Gold up by 3.98%, Zijin Mining International up by 2.45%, Chifeng Jilong Gold up by 2.41%, and Shandong Gold up by 2.07% [1] Gold Market Dynamics - Spot gold prices surged to $4000 per ounce, marking a historic high. This increase is attributed to a declining US dollar, a government shutdown in the US, and market speculation that the Federal Reserve may continue to lower interest rates despite high inflation [2] - Billionaire Ray Dalio stated that gold is a safer haven than the US dollar, drawing parallels to the 1970s when gold prices soared amid high inflation and economic instability [2][3] Company Performance - AI concept stocks in the Hong Kong market weakened, with significant declines in companies such as Huya Technology down nearly 8%, and Baidu Group down 4.8% [3] - Longwind Pharmaceutical, a new stock, opened significantly higher by over 218% on its first trading day, reaching nearly 200% increase at a price of 43.6 HKD, with a trading volume of 419 million HKD [3] - Longwind Pharmaceutical focuses on the research, development, and commercialization of inhalation technology and drugs for respiratory diseases, with its first approved product, CF017, capturing approximately 16% of the Chinese market for budesonide inhalation drugs by 2024 [4] Financial Performance - Longwind Pharmaceutical's revenue for the years 2022, 2023, and 2024 is projected to be 349 million RMB, 556 million RMB, and 608 million RMB respectively, with gross profits of 267 million RMB, 458 million RMB, and 491 million RMB for the same years [4] Future Market Outlook - Despite the current adjustments in the Hong Kong stock market, institutions remain optimistic about future trends. Analysts suggest that foreign capital inflows are accelerating, and both undervalued assets and technology sectors are becoming focal points for investment [5] - The ongoing bull market in A-shares and Hong Kong stocks is expected to continue, with strong market performance anticipated post the National Day holiday [5]

Group 1 - The core viewpoint of the news is the successful listing of Changfeng Pharmaceutical Co., Ltd. on the Hong Kong Stock Exchange, facilitated by ICBC International, highlighting the company's growth in the healthcare sector [1] - The issuance involved 41,198,000 shares at a final price of HKD 14.75 per share, raising approximately HKD 610 million (around USD 78 million) [1] - This project reflects ICBC International's commitment to promoting high-quality development in the healthcare industry and showcases its strength in serving major industry leaders [1] Group 2 - Changfeng Pharmaceutical focuses on the research, production, and commercialization of inhalation technology and drugs, specifically targeting respiratory diseases [2] - The company has received six product approvals from the National Medical Products Administration and the U.S. Food and Drug Administration, generating significant sales revenue [2] - This demonstrates Changfeng Pharmaceutical's capabilities in clinical development, production, regulatory affairs, and commercialization [2] Group 3 - ICBC International is a wholly-owned subsidiary of Industrial and Commercial Bank of China in Hong Kong, providing a range of financial services including corporate financing and market research [3] - The company leverages its parent bank's strong brand, financial strength, and extensive client base to serve both domestic and international capital markets [3] - ICBC International offers market research services covering macroeconomics, international financial markets, and key industries such as healthcare [3]

恒生科技指数报6543点，下跌6.90点，跌幅0.11%。 分析人士认为，在此前港股快速上涨背景下，市场积累了大量获利盘，部分资金选择获利了结，导致短期回调。此次下跌被视为技术性调整，尤其是在恒生 指数接近关键阻力区域时，市场出现反复是正常现象。 新股方面，长风药业（02652.HK）今日上市交易，截至发稿，长风药业报47港元，较发行价涨超218%。 长风药业深耕呼吸系统疾病治疗领域，主要专注于吸入技术及吸入药物的研发、生产及商业化，是少数几家拥有广泛吸入制剂产品组合的公司之一。公司开 发以患者为中心的新型疗法，以治疗部分最严重的呼吸系统及肺部疾病，已拥有覆盖广泛患者、医学专科及治疗领域的产品组合。截至目前，产品组合包括 6个获国家药监局或FDA批准的产品，以及20多款正在中国、美国及╱或欧洲等主要市场和东南亚及南美等新兴市场进行全球开发的产品，多款产品处于临 床试验后期阶段或PK-BE试验中，即将注册和商业化。 其他方面，恒生指数成分股中，京东健康（06618.HK）涨超3%、美的集团（00300.HK）、信义光能（00968.HK）涨超1%；龙湖集团（00960.HK）跌超 8%。恒生科技指数成分股中小鹏 ...

每经AI快讯，10月8日，长风药业港股IPO上市首日开盘大涨超218%，报47港元/股。 ...

Core Viewpoint - Changfeng Pharmaceutical (02652) has successfully listed its shares at a price of HKD 14.75 per share, raising approximately HKD 525 million, with a significant initial trading surge of 218.64% to HKD 47 per share, indicating strong market interest and investor confidence in the company’s prospects [1] Company Overview - Changfeng Pharmaceutical focuses on the research, development, production, and commercialization of inhalation technology and inhalation drugs, specifically targeting respiratory diseases [1] - The company has developed a diverse product portfolio that addresses a wide range of patients, medical specialties, and treatment areas [1] Regulatory Approvals and Market Performance - The company has received six product approvals from the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA), demonstrating its capabilities in clinical development, production, regulatory affairs, and commercialization [1] - CF017, an inhalation suspension of budesonide for the treatment of bronchial asthma, is the company’s first approved product, which quickly became part of China's centralized procurement plan after its approval in May 2021, leading to significant market growth [1] - According to Frost & Sullivan, CF017 is projected to capture approximately 16% of the Chinese budesonide inhalation drug market by sales volume in 2024 [1]

Core Viewpoint - Changfeng Pharmaceutical (02652) has successfully listed its shares at a price of HKD 14.75 per share, raising approximately HKD 525 million, with a significant initial trading increase of 218.64% to HKD 47 per share [1] Company Overview - Changfeng Pharmaceutical focuses on the research, development, production, and commercialization of inhalation technology and inhalation drugs, primarily targeting respiratory diseases [1] - The company has developed a diverse product portfolio that addresses a wide range of patients, medical specialties, and treatment areas [1] Regulatory Approvals and Market Performance - The company has received six product approvals from the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA), demonstrating its capabilities in clinical development, production, regulatory affairs, and commercialization [1] - CF017, an inhalation suspension of budesonide for the treatment of bronchial asthma, is the company's first approved product and has quickly gained market traction since its approval in May 2021 [1] Market Position - CF017 has been included in China's centralized procurement plan, leading to significant market growth [1] - According to Frost & Sullivan, CF017 is projected to capture approximately 16% of the Chinese budesonide inhalation drug market by 2024, based on sales volume [1]

点击查看公告原文>> 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 来源：新浪港股-好仓工作室 发行情况： ① 发行价：最终发行价格为14.75港元，公告未提及价格区间。 ② 发行股数：基础发行股 数为41,198,000股H股，未提及超额配售权股数。 ③ 募集资金规模：所得款项总额为6.077亿港元，所得 款项净额为5.254亿港元。 ④ 认购倍数：香港发售认购倍数为6,697.80倍，国际配售认购倍数为12.74 倍。 ⑤ 回拨情况：未触发回拨机制，香港发售股份数目为4,120,000股H股，占全球发售股份数目之 10.00%；国际配售股份数目为37,078,000股H股，占全球发售股份数目之90.00%。 ⑥ 基石投资者：公告 未提及基石 ...

其中，香港公开发售获6697.80倍认购，国际发售获12.74倍认购。 长风药业(02652)发布公告，公司全球发售约4119.8万股股份，香港公开发售占10%，国际发售占90%。 最终发售价为每股14.75港元，全球发售净筹约5.25亿港元。每手500股，预期将于2025年10月8日(星期 三)上午九时正(香港时间)开始在联交所买卖。 ...

其中，香港公开发售获6697.80倍认购，国际发售获12.74倍认购。 智通财经APP讯，长风药业(02652)发布公告，公司全球发售约4119.8万股股份，香港公开发售占10%， 国际发售占90%。最终发售价为每股14.75港元，全球发售净筹约5.25亿港元。每手500股，预期将于 2025年10月8日(星期三)上午九时正(香港时间)开始在联交所买卖。 ...